Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

FAT jabs are shrinking supermarket sales, with grocery volumes falling 0.4% year-on-year, new figures reveal. Popular Ozempic ...

Mounjaro has been approved for both type 2 diabetes and weight loss, but access will be limited by strict eligibility ...

As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...

WEIGHT loss jabs may also help ward off dementia, a new study suggests. Researchers found that semaglutide – the active ...

Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment roughly a month after it began over concerns about what it said was illegal mass ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

Gone are the days of battling obesity with a limited toolbox. With more weight loss supplements and drugs on the market than ever before, deciding which medication is right for you isn' ...

Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people, but a new ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.